The First and Only TIGIT/TGFβ Bispecific Antibody Under Research in the World

The marketing approval of SinoCellTech's new anti-CD20 monoclonal antibody ripertamab aroused the attention of the industry in China this week. While the clinical trial application of the AK130 injection developed by another Chinese company Akeso was accepted, making it the first and the only TIGIT/TGFβ bispecific antibody under research in the world. Other pharma news collected this week features 26 pieces of information covering topics on drug review, R&D, business, and listing. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com